Ligand is a biopharma technology and capital partner that provides technology and financing solutions to advance tomorrow's medicines.

Ligand

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

HSTS

Google Font API

Google Analytics

DNSSEC

Chief People Officer

Audrey Warfield-Graham

Matthew Korenberg

Founder & CSO

Patrick Sims

Member, Board of Directors

Sunil Patel

Vice President

Anil Nair

VP, Protein Sciences

Jeff Allen

Vice President, Corporate Controller

Jenny Li

SVP, Biology & Scientific Affairs

Keith Marschke

Vice President, Chemistry & Pharmaceutical Sciences

Lin Zhi

Vice President, Business Development

Louis J. Cantolupo

Todd C. Davis

John L. Higgins

Melanie Herman

Chief Accounting Officer and Interim CFO

Brook Byers

Founder

Executive Vice President, Finance & CFO

Richard Baxter

Senior Vice President of Investment Operations

Matthew Foehr

President & Chief Operating Officer

Chief Executive Officer & Director

Bob Chen

Director, Systems Engineering and Site Head

Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.

Novan is a clinical-stage drug development company developing deliverable nitric oxide.

California Companies With More Than 50 Employees (Top 10K)

Early Stage Venture Investors with Investments in Western US (Top 10K)

United States Medical Companies (Top 10K)

Companies With More Than $10M in Revenue (Top 10K)

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

Post-IPO Debt - Ligand Pharmaceuticals

Seed Round - Ligand Pharmaceuticals

Computer and Software Services and Scientific Services

San Diego

California

United States

North America

Ligand Pharmaceuticals

Benchmark Maintains Buy on Ligand Pharmaceuti...

Invios GmbH. (10/15/24). "Press Release: Invios Raises €8.2 Million in a Series A to Finance Pipeline Progress in Immuno-oncology". Vienna.

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand Pharmaceuticals Officer Sells Shares

Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook

Ligand Pharmaceuticals Says President, Operating Chief Korenberg to Exit

Ligand Pharmaceuticals COO Matthew Korenberg to depart (NASDAQ:LGND)

A chemically modified cyclodextrin used to enhance the solubility and stability of drugs, widely utilized by pharmaceutical companies in drug development.

Ligand manages a diverse portfolio of royalties from over 100 partnered commercial and development stage programs across various therapeutic areas.

Ligand invests in the clinical development and commercialization of high-value medicines, focusing on late-stage assets to generate royalties.

France

Europe

India

Asia

Australia

Oceania

Turkey

HTML5

Lightbox

Google Fonts

HubSpot Marketing Hub

Amazon EC2

jQuery

Apache Server

Microsoft Outlook

HubSpot Forms

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

news impact assignment basic	general	Dec 5, 2024 5:27 PM	38015b42
public peers	general	Jul 13, 2024 9:48 AM	243301f9
news daily refresh	general	Dec 23, 2024 12:00 AM	fbe4becf
news processing daily refresh	general	Dec 20, 2024 7:48 PM	6db1737e
news impact assignment daily	general	Dec 20, 2024 7:41 AM	e9e03006
news processing basic	general	Dec 4, 2024 5:47 PM	fb2c0adb
company summary	general	Dec 20, 2024 10:01 AM	2d6d1cf6
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	ce798488
crunchbase profile	general	Nov 25, 2024 9:21 AM	0900a7fc
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:06 PM	83d7ce3e
peers	general	Jul 13, 2024 9:48 AM	0fd2b535
news basic	general	Dec 4, 2024 2:13 PM	66876f82
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:LIGAND

Ligand

Last Close

116.55

22/11 21:00

Market Cap

1.73B

Beta: -

Volume Today

90.76K

Avg: -